Share

    


Home / Search Results

Search Results

Search Publications

Search Again?

Filter By Content Type

Filter By Topic

A total of 144 respondents took this year’s survey, with cancer program administrators representing more than half (53%) and an additional quarter (23%) identifying themselves as cancer program leadership. In the Past 2 Years, to Ensure Financial Sustainability… LIVE POLLING AT THE 2019 ACCC NATIONAL ONCOLOGY CONFERENCE In a follow-up question, almost ¾ said the affiliation, agreement, …
When U.S. Representative John Lewis (D-GA) announced in December 2019 that he had stage IV pancreatic cancer, he faced the disease as he faced his lifelong struggle for civil rights – with incredible courage. “I have been in some kind of fight – for freedom, equality, basic human rights – for nearly my entire life. I have never faced a fight quite like the one I have now. This month in a routine medical …
Rockville, MD — The Association of Community Cancer Centers (ACCC) announces the recent hiring of Colleen Cancio as Director of Development and Strategic Alliances. In her new role, Colleen will work to ensure sustainability for ACCC’s key educational programs and initiatives, with specific emphasis on the organization’s efforts to expand access to clinical trials in oncology and to improve cancer …
How do interest specialists outside the field of oncology in participating in an inter-specialty immune-related adverse events (irAEs) tumor board? Cleveland Clinic discovered the key is to recruit physician champions who are not oncologists.
At Jefferson Health, detecting, diagnosing, and monitoring immune-related adverse events (irAEs) that may results from treatment with immunotherapies for cancer is a group effort. To provide scheduling flexibility and the ability to respond to queries as they arise, the 11-member Jefferson Immuno-Oncology Working groups meets online on an as-needed basis.
Johns Hopkins was one of the first institutions to use immunotherapies to treat intractable cancers. Because IO therapies can affect any of the body's organ systems, there was early recognition of the value of having a multidisciplinary team of organ specialists who could bring their expertise to the treatment of patients experiencing immune-related adverse events (irAEs).
Rockville, MD — Since the inception of the Center for Medicare and Medicaid Innovation (CMMI) and the Innovation Center’s launch of the Oncology Care Model (OCM), the Association of Community Cancer Centers (ACCC) has deeply valued the opportunity to support stakeholders through its Oncology Care Model Collaborative. ACCC congratulates Brad Smith on his appointment as Director of CMMI and Senior Advisor …
We sat down with journalist Mary Elizabeth Williams, one of the first patients treated with combination immunotherapy, to discuss her experience as an IO patient and how to bridge communication gaps among patients, doctors, and researchers.
The Association of Community Cancer Centers (ACCC) Immuno-Oncology Institute (the Institute) recently brought together experts from relevant healthcare sectors and Institute leadership for a one-day meeting focused on the application of telemedicine in oncology and, specifically, in delivery of immunotherapy for cancers. The Telemedicine Roundtable, held in December, is one piece of a larger ACCC educational …
Rockville, MD — The Association of Community Cancer Centers (ACCC) congratulates the entire oncology community on the achievement of the largest one-year drop in cancer mortality—the record decline in annual cancer deaths was measured from 2016 to 2017. The numbers were reported in the American Cancer Society’s yearly Cancer Statistics, 2020, report released January 8. The study authors attribute …
In preparation for the ACCC 46th Annual Meeting & Cancer Center Business Summit (AMCCBS) in Washington, D.C. on March 4-6, we are talking with several featured speakers about the topics they plan to address at the summit. Debra Patt, MD, MPH, MBA—a breast cancer specialist in Austin, Texas, whose research focuses on imaging informatics for breast cancer, clinical decision support systems, predictive …
cSCC flyer - The Angeles Clinic Advanced Cutaneous Squamous Cell Carcinoma: Immuno-Oncology and the Evolving Landscape of Multidisciplinary Care Participate in an informative discussion on the data regarding the epidemiology of cutaneous squamous cell carcinoma (cSCC) and come away with an understanding of the potential preventative strategies for skin cancer including cutaneous squamous …
cSCC flyer: NYU Langone High Risk Cutaneous Squamous Cell Carcinoma: Recognition and Management Join a best practices seminar to identify lesions suspicious for cutaneous squamous cell carcinoma (cSCC), better understand the clinical and histologic features of high risk cSCC, and learn about management options.  Seating is limited to the first 50 registrants. Speaker: Desiree …
This article explores Johns Hopkins University’s unique approach to recruiting specialists outside the field of oncology to participate in its virtual immune-related Toxicity Team. In 2015, when Jarushka Naidoo, MBBCh, began working at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, she joined one of the first institutions to use immunotherapies to treat intractable …
Virtual Toxicity Team Cleveland Clinic This article explores how Cleveland Clinic is taking a unique approach to recruiting specialists outside the field of oncology to participate in immunotherapy multi- specialty immune-related adverse events (irAE) tumor boards. According to Pauline Funchain, MD, the right champions are essential to attracting the interest of specialists in the …
This article explores how Jefferson Health is taking a unique approach to recruiting specialists outside the field of oncology to participate in an Immuno-oncology Working Group. At Jefferson Health, detecting, diagnosing, and monitoring the irAEs that immuno- therapy patients can manifest during treat- ment is a group effort in a virtual space. Rather than meeting in person at a desig- nated …
In preparation for the ACCC 46th Annual Meeting & Cancer Center Business Summit in Washington, D.C. on March 4-6, we are talking with several featured speakers about the topics they plan to address at the summit. Lori Marcus—the Direct-to-Patient Workstream Lead at the Kraft Precision Medicine Accelerator—and Anne Quinn Young, MPH—Chief Marketing and Development Officer at the Multiple Myeloma …
As more patients are treated with single and combination immunotherapies for cancer, early identification and management of immune-related adverse events (irAEs) is critical to achieving desired outcomes with these new drugs. ACCCBuzz recently talked with Matthew R. Zibelman, MD, for perspective on irAE management in patients treated with immune checkpoint inhibitor therapy. Dr. Zibelman is a genitourinary …
We talk to a medical oncologist in a rural Montana community about the realities of rural cancer care, the importance of community oncology, and how he navigates common barriers to quality care.
In preparation for the ACCC 46th Annual Meeting & Cancer Center Business Summit in Washington, D.C. on March 4-6, we are talking with several featured speakers about the topics they plan to address at the summit. Susan Dentzer—a health policy expert and Senior Policy Fellow at The Duke-Margolis Center for Health Policy—will speak about "Disruptive Innovations That Could Change the Delivery of Cancer …